AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
232.08
+7.39 (3.29%)
At close: Feb 27, 2026, 4:00 PM EST
231.13
-0.95 (-0.41%)
After-hours: Feb 27, 2026, 7:59 PM EST
AbbVie Employees
AbbVie had 57,000 employees as of December 31, 2025. The number of employees increased by 2,000 or 3.64% compared to the previous year.
Employees
57,000
Change (1Y)
2,000
Growth (1Y)
3.64%
Revenue / Employee
$1,072,982
Profits / Employee
$73,439
Market Cap
410.36B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 57,000 | 2,000 | 3.64% |
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| Eli Lilly and Company | 50,000 |
ABBV News
- 1 day ago - Best Dividend Aristocrats For March 2026 - Seeking Alpha
- 2 days ago - Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie - Seeking Alpha
- 4 days ago - AbbVie to Present at the TD Cowen 46th Annual Health Care Conference - PRNewsWire
- 5 days ago - AbbVie to invest $380 million to expand US manufacturing in Illinois - Reuters
- 5 days ago - AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States - PRNewsWire
- 8 days ago - U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) - PRNewsWire
- 9 days ago - AbbVie Declares Quarterly Dividend - PRNewsWire
- 11 days ago - AbbVie: Dominating Immunology While Building Oncology Upside - Seeking Alpha